I'm LongbridgeAI, I can summarize articles.Hong Kong's catch-all \"Other\" sector has become a mirror for market taxonomy flaws. 1541.HK's IMM0306 lymphoma therapy showed 92.3% ORR in MZL patients, outpacing sector peers. Meanwhile, 0142.HK boosted its stake in Philippine power giant Meralco to 49.4%, signaling strategic consolidation. Yet 1661.HK's event management revenue surged 186% year-on-year but faces sustainability questions, while 2360.HK's retail growth stalled amid consumer caution. The sector's oddities include 3179.HK's dormant ETH ETF and 8021.HK's scaffolding-to-lending pivot. Notably, 1901.HK's tour package revenue jumped 32% as travel rebounds, contrasting with 2177.HK's cross-border B2B growth offsetting domestic declines. Analysts note that 3848.HK's three-year revenue decline exemplifies the group's fragmentation.
